Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study

Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Hiroki Sakaguchi, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yuko Tsuge, Takeki Uehara
doi: https://doi.org/10.1101/2022.06.22.22276792
Hiroshi Mukae
1Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Yotsuyanagi
2The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norio Ohmagari
3Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yohei Doi
4Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
5Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroki Sakaguchi
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takuhiro Sonoyama
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Genki Ichihashi
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takao Sanaki
7Pharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keiko Baba
7Pharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuko Tsuge
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeki Uehara
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: takeki.uehara{at}shionogi.co.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

This phase 2b part of a randomized phase 2/3 study assessed the efficacy and safety of ensitrelvir for mild-to-moderate coronavirus disease 2019 (COVID-19). Patients were randomized (1:1:1) to orally receive ensitrelvir fumaric acid 125 mg (375 mg on day 1; n=140) or 250 mg (750 mg on day 1; n=140) or placebo (n=141) once daily for 5 days. Compared with placebo, the change from baseline in severe acute respiratory syndrome coronavirus 2 titer (measured as log10 50% tissue-culture infectious dose) on day 4 was significantly greater with ensitrelvir 125 mg and 250 mg (differences from placebo: −0.41, P<0.0001 for both). The total score of predefined 12 COVID-19 symptoms showed an improving trend with ensitrelvir treatment without a significant intergroup difference. Most adverse events were mild in severity. Ensitrelvir treatment demonstrated a favorable antiviral efficacy and potential clinical benefit with an acceptable safety profile. (Japan Registry of Clinical Trials identifier: jRCT2031210350)

Competing Interest Statement

H. Mukae has received funding relevant to the submitted work from Shionogi and grants from Taisho Pharma; lecture fees from Pfizer, MSD, Shionogi, and Taisho Pharma; and advisory fees from Pfizer, MSD, and Shionogi outside the submitted work. H. Yotsuyanagi has received consulting fees from Shionogi, lecture fees from Shionogi and ViiV Healthcare, and travel support from Shionogi outside the submitted work. He serves as an advisory board member of Shionogi and President of the Japanese Society of Infectious Diseases. Y. Doi has received grants from Shionogi and Entasis; consulting fees from Shionogi, Meiji Seika Pharma, Gilead Sciences, GSK, MSD, Chugai, and bioMerieux; and lecture fees from MSD, AstraZeneca, Shionogi, and Teijin Healthcare outside the submitted work and serves as an advisory board member of FujiFilm. H. Sakaguchi, T. Sonoyama, G. Ichihashi, T. Sanaki, K. Baba, Y. Tsuge, and T. Uehara are full-time employees of Shionogi & Co., Ltd., and may have stocks or stock options. N. Ohmagari declares no conflict of interest.

Clinical Trial

jRCT2031210350

Funding Statement

This study was sponsored by Shionogi & Co., Ltd., and financially supported by the Organization of the Ministry of Health, Labour and Welfare.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was reviewed and approved by the institutional review boards of all participating institutions listed in Supplementary Table 1. All patients or their legally acceptable representatives provided written informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Shionogi & Co., Ltd. is committed to disclosing the synopses and results of its clinical trials and sharing the clinical trial data with researchers on reasonable request. For further details, please refer to the websites of Shionogi & Co., Ltd. (https://www.shionogi.com/shionogi/global/en/company/policies/shionogi-group-clinical-trial-data-transparency-policy.html) and Vivli (https://vivli.org/).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 26, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Hiroki Sakaguchi, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yuko Tsuge, Takeki Uehara
medRxiv 2022.06.22.22276792; doi: https://doi.org/10.1101/2022.06.22.22276792
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Hiroki Sakaguchi, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yuko Tsuge, Takeki Uehara
medRxiv 2022.06.22.22276792; doi: https://doi.org/10.1101/2022.06.22.22276792

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (433)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3308)
  • Dentistry and Oral Medicine (365)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1174)
  • Epidemiology (13391)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5168)
  • Geriatric Medicine (482)
  • Health Economics (784)
  • Health Informatics (3282)
  • Health Policy (1144)
  • Health Systems and Quality Improvement (1197)
  • Hematology (432)
  • HIV/AIDS (1021)
  • Infectious Diseases (except HIV/AIDS) (14648)
  • Intensive Care and Critical Care Medicine (914)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4941)
  • Nursing (262)
  • Nutrition (733)
  • Obstetrics and Gynecology (887)
  • Occupational and Environmental Health (796)
  • Oncology (2527)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (546)
  • Pediatrics (1304)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4221)
  • Public and Global Health (7522)
  • Radiology and Imaging (1710)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (499)
  • Sports Medicine (425)
  • Surgery (550)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (206)